Teva Pharma (TEVA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Remains Bullish as Teva Pharma (TEVA) Awaits IPR Ruling
August 15, 2016 2:00 PM EDTLeerink Partners reiterated an Outperform rating and $66.00 price target on Teva Pharma (NYSE: TEVA) ahead of an IPR ruling on three TEVA patents.
Analyst Jason Gerberry commented, "We continue to eagerly await the IPR (inter partes review) ruling on three TEVA patents that cover... More
Guggenheim Reiterates Buy on Teva Pharma (TEVA) Following AGN Deal
August 15, 2016 7:21 AM EDTGuggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) following the close of the company's AGN generics deal earlier this month. Later this month, TEVA will receive two decisions on the IPR challenge for Copaxone 40mg, about whether three patents have been invalidated and if a fourth will be considered for IPR.
Analyst Louise Chen commented, "After closing the AGN generics deal... More
